Navigation Links
Targeted Prostate Cancer Biopsy and Cancer Treatment Earns Acceptance From Nation's Top Prostate Specialists

TargetScan(R) Technology passes 3,500-procedure milestone as the system becomes available in more medical centers and private practices across the country

ST. LOUIS, Jan. 16 /PRNewswire/ -- To date, more than 3,500 prostate biopsies and subsequent cancer treatment procedures have been conducted using the proprietary TargetScan(R) technology, adopted by prostate specialists in search of more effective cancer treatments with fewer side effects.

The TargetScan technology has been shown to accurately map the prostate, delivering precise, repeatable biopsies that record results from specific locations within the gland. The ability to target specific locations may deliver optimal cancer treatments while reducing negative side effects, such as erectile dysfunction and incontinence that result from more aggressive cancer therapies.

TargetScan collects 3-D images using a proprietary stationary ultrasound probe; leads physicians in systematically mapping prostate locations; and guides biopsy sampling and/or cancer therapies through needle placement within the defined template map. The original technology was introduced in 2005 and is now used at the nation's top urologic centers, including Washington University, Duke University, Emory University, New York University and the University of Michigan - and is being adopted in private practice by urologists interested in bringing state-of-the-art care to their offices.

"TargetScan is an excellent tool that reliably defines where cancer exists in the prostate and maps the prostate in a reproducible manner so I may accurately follow a patient's progress and cancer status over time," explains James K. Bennett, M.D., a leading urologist in private practice in Atlanta. "This is the future of prostate cancer diagnosis and treatment for men who seek alternatives to extreme surgical treatments and negative side effects."

Gerald L. Andriole, Jr., M.D., Professor and Chief of Urologic Surgery at Washington University School of Medicine in St. Louis is a member of a multi-center team that conducted an evaluation of TargetScan. Their study was published in the British Journal of Urology and showed that TargetScan template guided biopsy technology potentially produces a higher cancer detection rate for first time biopsies and a more accurate assessment of grade. "More accurate biopsies and targeted cancer treatments may help patients achieve better results with fewer negative side effects," says Dr. Andriole.

About Envisioneering Medical Technologies

Envisioneering Medical Technologies, based in St. Louis, Mo., offers technology to support the continuum of care for the prostate - from accurate biopsies to targeted cancer treatment. TargetScan Touch(TM) was introduced in late 2008, incorporating a touch-screen interface with the TargetScan(R) Ultrasound Probe technology platform. For more information please visit

SOURCE Envisioneering Medical Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anthem Blue Cross and Blue Shield Introduces SmartSense, Price-Conscious Plans Targeted at the Uninsured
2. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
3. Experts: Targeted agricultural investments will yield high results, slash poverty in Africa
4. Combining targeted therapy drugs may treat previously resistant tumors
5. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
6. CVS/pharmacy Announces Pharmacy Health Care Savings Program Targeted at the Uninsured
7. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
8. Targeted radiation therapy can control limited cancer spread
9. Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease
10. Personalizing medicine: New research shows potential of targeted therapies for cancer
11. Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... ... 26, 2015 , ... Ministers, senior government and UN agencies, ... Centres of Excellence, and public R&D institutions, civil societies and other partners gathered ... 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based drug ... their sobriety and show through pictures what a positive difference it makes. The ... with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and ... Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: ... Rugen Therapeutics, a start-up  biotechnology company focused on ... disorders and funded by the F-Prime Biomedical Research ... into an exclusive collaboration to support the discovery ... Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 USP 800 applies to all ... pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home ... also covers all entities which store, prepare, transport, ... healthcare institutions, patient treatment clinics, physicians, practice facilities, ... --> What is the purpose of ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
Breaking Medicine Technology: